U.S. National Institutes Of Health, India's Cadila Healthcare Join Forces To Develop A New HPV Vaccine
This article was originally published in PharmAsia News
Executive SummarySINGAPORE - India's Zydus Cadila has joined hands with the U.S.-based National Institutes of Health to develop a new prophylactic vaccine against human papilloma virus - known to be a major cause of cervical cancer
You may also be interested in...
Sanofi Beats GSK To Buy Merieux Alliance's Stake In India's Shantha Biotech; Move Aimed At Stronger Vaccines Business In Emerging Markets
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).